Ascitic ovarian cancer is an adequate preclinical model of carcinomatosis to study intraperitoneal chemoperfusion treatment

To study the mechanisms underlying the effects of intraperitoneal chemoperfusion and to develop the optimal chemoperfusion regimen, an animal model of peritoneal carcinomatosis closely resembles a human model of peritoneal carcinomatosis is required. In our study, the model of peritoneal carcinomatosis in rats with ascitic ovarian cancer was used. material and methods. There were three groups of rats with ascitic ovarian cancer: 1 – the control group (n=15) having no treatment; 2 – rats receiving normothermic intraperitoneal chemoperfusion with cisplatin, 40 mg/kg (n=12); 3 – rats receiving hyperthermic intraperitoneal chemoperfusion with cisplatin, 20 mg/kg (n=14). All animals were euthanized with subsequent autopsy. results. Ascitic ovarian cancer developed in 100 % of the animals injected with the tumor cells. The median overall survival of rats in the control group was 9.5 days. At autopsy, all rats had ascites, and rats surviving 15‒17 days after the tumor cell injection had white tumor nodes measuring 1–3 mm in the greater omentum, intestinal mesentery, parietal and visceral peritoneum. The nodes were histologically verified as metastases of low-differentiated ovarian tumor. In 2 and 5 rats from groups 2 and 3 respectively, metastases in paratracheal lymph nodes and tumor hydrothorax were detected with no evidence of peritoneal carcinomatosis. The median survival of rats in groups 2 and 3 was significantly higher than that in the control group, being 37.5 and 25.5 months, respectively (р=0,256). conclusion. This in vivo study proved that localization of ascitic ovarian tumor, development of the tumor in all animals injected with tumor cells, fast ascites progression and peritoneal carcinomatosis make this ascitic ovarian cancer an adequate preclinical model of peritoneal carcinomatosis to study intraperitoneal chemoperfusion. Further studies are needed to understand the reasons and mechanisms of the tumor hydrothorax development in rats after intraperitoneal chemoperfusion.

ascitic ovarian cancer, peritoneal carcinomatosis, intraperitoneal chemoperfusion, preclinical model, cisplatin, rats, survival

1. Morano W.F., Khalili M., Chi D.S., Bowne W.B., Esquivel J. Clinical studies in CRS and HIPEC: Trials, tribulations, and future directions. A systematic review. J Surg Oncol. 2018 Feb; 117 (2): 245–259. doi: 10.1002/jso.24813.

2. Sugarbaker P.H. Revised clinical pathway for the management of peritoneal metastases from colorectal cancer using NCCN 2017 guidelines. Colorectal Cancer. 2017. Dec; 6 (3): 75–82. doi: 10.2217/ crc‐2017‐0016.

3. Sugarbaker P.H. Cytoreductive surgery and hyperthermic intraperi‐ toneal chemotherapy in the management of gastrointestinal cancers with peritoneal metastases: Progress toward a new standard of care. Cancer Treat Rev. 2016. Jul; 48: 42–9. doi: 10.1016/j.ctrv.2016.06.007.

4. Neuwirth M.G., Alexander H.R., Karakousis G.C. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. J Gastrointest Oncol. 2016. Feb; 7 (1): 18–28. doi: 10.3978/j.issn.2078‐6891.2015.106.

5. Степанов И.В., Падеров Ю.М., Афанасьев С.Г. Перитонеальный канцероматоз. Сибирский онкологический журнал. 2014; 5: 45–53. [Stepanov I.V., Paderov Yu.M., Afanasyev S.G. Peritoneal carcinomatosis. Siberian Journal of Oncology. 2014; 5: 45–53. (in Russian)].

6. Van Driel W.J., Koole S.N., Sikorska K., van Leeuwen J.H.S., Schreuder H.W.R., Hermans R.H.M., de Hingh I.H.J.T., van der Velden J., Arts H.J., Massuger L.F.A.G., Aalbers A.G.I., Verwaal V.J., Kieffer J.M., Van de Vijver K.K., van Tinteren H., Aaronson N.K., Sonke G.S. Hyper‐ thermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018. Jan; 378: 230–240. doi: 10.1056/NEJMoa1708618.

7. Spiliotis J., Halkia E., de Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy – current perspectives. Curr Oncol. 2016. Jun; 23 (3): e266–75. doi: 10.3747/ co.23.2831.

8. Погосянц Е.Е., Пригожина Е.Л., Еголина Н.А. Перевиваемая опухоль яичника крысы. Вопросы онкологии. 1962; 11: 29–36. [Pogosyants Ye.Ye., Prigozhina Ye.L., Yegolina N.A. Transplanted ovarian rat tumor. Problems in Oncology. 1962; 11: 29–36. (in Russian)].

9. Трашков А.П., Панченко А.В., Васильев А.Г., Артеменко М.Р., Богомолов Б.Н. Особенности роста экспериментальной асцитной опухоли яичников крыс и изменение гематологических показателей у животных‐опухоленосителей под действием гемцитабина. Вестник Российской военно‐медицинской академии. 2012; 2 (38): 90–96. [Trashkov A.P., Panchenko A.V., Vasiliev A.G., Artemenko M.R., Bogomolov B.N. Experimental rodent ascitic ovarial tumor growth peculiarities and hemcit‐ abin effects upon hematological parameters in rats with tumor. Herald of Russian military medical Academy. 2012; 2 (38): 90–96. (in Russian)].

10. Тузеева А.Ю., Долгова Д.Р., Абакумова Т.В., Сенина Д.Н. Изучение про‐ и антиоксидантного статуса эритроцитов при про‐ грессировании экспериментального рака яичников. Фундаментальные исследования. 2014; 12–1: 145–149. [Tuzeeva A.Y., Dolgova D.R., Abakumova Т.V., Senina D.N. Study pro and antioxidant status of erythrocytes in the progression of experimental ovarian cancer. Fundamental research. 2014; 12–1: 145–149. (in Russian)].

11. Соболев И.В., Семенов А.Л., Глушаков Р.И., Беспалов В.Г., Багатурия Г.О., Прошин С.Н., Тапильская Н.И. Лекарственное моделирование тиреоидного статуса и длительность жизни крыс с перевитой асцитной опухолью яичника. Экспериментальная и клиническая фармакология. 2017; 80 (5): 16–21. [Sobolev I.V., Semenov A.L., Glushakov R.I., Bespalov V.G., Bagaturiya G.O., Proshin S.N., Tapil’skaya N.I. Drug Altered Thyroid Status and Survival Life of Rats with Ovarian Tumor Xenografts. Russian Journal of Experimental and Clinical Pharmacology. 2017; 80 (5): 16–21. (in Russian)].

12. Беляева О.А., Беспалов В.Г., Сенчик К.Ю., Киреева Г.С., Стуков А.Н., Аристова В.А., Иванцов А.О., Вышинская Е.А., Майдин М.А., Семенов А.Л., Александров В.А., Беляев А.М. Экспериментальная технология химиоперфузионного лечения канцероматоза брюшной полости при раке яичника. Вопросы онкологии. 2014; 60 (1): 71–78. [Belyaeva O.A., Bespalov V.G., Senchik K.Yu., Kireeva G.S., Stukov A.N., Aristova V.A., Ivantsov A.O., Vyshinskaya E.A., Maidin M.A., Semenov A.L., Alexandrov V.A., Belyaev A.M. Experimental technology of chemoperfu‐ sion treatment for abdominal carcinomatosis in ovarian cancer. 2014; 60 (1): 71–78. (in Russian)].

13. Han X., Papadopoulos A.J., Jones T.A., Sheer D., Raju K.S. SR8: the establishment and characterisation of a new ovarian carcinoma cell line and xenograft model. Eur J Cancer. 1996 Jan; 32 A(1): 160–7.

14. Berns E.M., Bowtell D.D. The changing view of high‐grade serous ovarian cancer. Cancer Res. 2012 Jun 1; 72 (11): 2701–4. doi: 10.1158/0008‐5472.CAN‐11‐3911.

15. Kerbel R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived‐but they can be improved. Cancer Biol Ther. 2003. Jul‐Aug; 2 (4 Suppl 1): S134–9.

16. Friedlander M.L., Russell P., Taylor I.W., Tattersall M.H.N. Ovar‐ ian tumour xenografts in the study of the biology of human epithelial ovarian cancer. Br J Cancer. 1985. Mar; 51 (3): 319–333.

17. Baratti D., Kusamura S., Laterza B., Balestra M.R., Deraco M. Early and long‐term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Gastroin‐ test. Oncol. 2010. Jan 15; 2 (1): 36–43. doi: 10.4251/wjgo.v2.i1.36.

18. Canda A.E., Sokmen S., Terzi C., Arslan C., Oztop I., Karabulut B., Ozzeybek D., Sarioglu S., Fuzun M. Complications and toxicities after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2013 Apr; 20 (4): 1082–7. doi: 10.1245/s10434‐012‐ 2853‐x.